Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million

Agenus Inc.

Agenus Inc.

AGEN

0.00
  • Agenus posted Q1 2026 revenue of USD 33.7 million, including USD 4.6 million in pre-commercial product revenue, while operating income swung to USD 15.1 million.
  • Net income swung to USD 39.2 million, while cash and cash equivalents rose to USD 35 million.
  • Paid named-patient activity broadened to additional countries in South and Central America and Europe; in April, BAP Pharma was named global partner for BOT+BAL access programs.
  • Phase 3 BATTMAN trial began patient enrollment in April, evaluating botensilimab plus balstilimab versus best supportive care in refractory MSS/pMMR metastatic colorectal cancer.
  • CEO Garo H. Armen said maturing BOT+BAL data, including durability of survival outcomes in refractory MSS colorectal cancer, underpins planned regulatory submissions in the US and Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260511199340) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.